Corifollitropin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Corifollitropin alfa: From Controlled Ovarian Stimulation to Gastroduodenitis
One-Sentence Summary
Corifollitropin alfa is a long-acting follicle-stimulating hormone (FSH) analogue, originally used for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) — administered as a single subcutaneous injection that maintains FSH activity for approximately 7 days. The TxGNN model predicts it may be effective for Gastroduodenitis, with a prediction score of 99.65%. Currently, there are 0 clinical trials and 0 publications directly supporting this repurposing direction, and the mechanistic plausibility is assessed as very low.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Controlled ovarian stimulation (ART) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.65% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Corifollitropin alfa (brand name: Elonva) is an engineered long-acting FSH analogue created by fusing the FSH β-subunit with a carboxy-terminal peptide (CTP) from human chorionic gonadotrophin (hCG). This modification extends the plasma half-life to approximately 65–70 hours, enabling sustained follicular stimulation from a single subcutaneous injection over 7 days — replacing the first week of daily FSH injections in a standard ART protocol.
Detailed mechanism of action data is not available in the current evidence pack. Based on known pharmacology, Corifollitropin alfa binds and activates FSH receptors (FSHR), which signal primarily through the cAMP–PKA pathway. FSHR expression is highly tissue-specific, predominantly found in ovarian granulosa cells and testicular Sertoli cells. Gastroduodenitis, by contrast, is driven by H. pylori infection (~70% of cases) or NSAID-induced mucosal injury, and its core inflammatory pathways (IL-1β, TNF-α, NF-κB) have no established intersection with FSHR signalling.
While isolated studies have described minor immunomodulatory properties of FSH — such as modulation of Th17/Treg balance — none has linked this to gastroduodenal inflammation specifically. The high TxGNN prediction score most likely reflects non-specific propagation through shared inflammation nodes in the knowledge graph rather than a genuine biological signal. Overall mechanistic plausibility for this repurposing direction is assessed as very low.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Corifollitropin alfa is not registered or marketed in Singapore. No Health Sciences Authority (HSA) authorisations are currently on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All 10 TxGNN-predicted indications for Corifollitropin alfa carry an L5 evidence level (model prediction only, no supporting studies), and the top-ranked indication — gastroduodenitis — lacks any clinical trial, preclinical, or mechanistic evidence. The prediction score of 99.65% is almost certainly a knowledge graph artefact driven by non-specific inflammation node connectivity rather than a pharmacologically meaningful signal. Among the 10 predictions, pulmonary hypertension (rank 6) represents the sole indication with a marginally more plausible mechanistic hypothesis (putative FSHR expression in pulmonary vascular smooth muscle cells and potential BMP/BMPR2 pathway overlap), warranting placement on a long-term observation list, but still far from actionable.
To proceed, the following is needed:
- FSHR expression profiling in gastric and duodenal mucosa tissue to determine whether a biological target exists
- Preclinical data (in vitro or animal models) demonstrating any FSH or FSHR-mediated effect on gastroduodenal inflammatory pathways
- Full safety profile for Corifollitropin alfa (package insert warnings, contraindications, and adverse event data)
- Knowledge graph audit to determine whether TxGNN predictions are driven by genuine pharmacological associations or non-specific inflammation-node propagation across all 10 predicted indications
- Singapore regulatory pathway assessment if any future evidence warrants escalation — given zero current HSA registrations, a full new drug application would be required
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.